Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback